Holen Sie sich die Stockscreener-App
66.98
3.54%
2.29
Handel nachbörslich:
72.19
5.21
+7.78%
Schlusskurs vom Vortag:
$64.69
Offen:
$64.9
24-Stunden-Volumen:
6.29M
Relative Volume:
2.15
Marktkapitalisierung:
$12.68B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-12.16
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
+5.48%
1M Leistung:
+18.09%
6M Leistung:
+29.93%
1J Leistung:
-4.04%
1-Tages-Spanne:
$64.02
$67.31
1-Wochen-Bereich:
$62.39
$67.31
52-Wochen-Spanne:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
66.98 | 12.25B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
564.88 | 213.17B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
214.06 | 152.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.94 | 50.36B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
144.69 | 41.49B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
213.88 | 36.86B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp (EXAS) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Exact Sciences Reports Record Q3 Revenue and Raises Guidance - TipRanks
Transcript : Exact Sciences Corporation, Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Exact Sciences Q3 2025 slides: 20% revenue growth, guidance raised - Investing.com
Earnings call transcript: Exact Sciences beats Q3 2025 EPS forecasts - Investing.com
EXACT SCIENCES CORP SEC 10-Q Report - TradingView
Exact Sciences: Q3 Earnings Snapshot - Journal Times
Exact Sciences Corp (EXAS) Q3 2025 Earnings: Revenue Surpasses E - GuruFocus
Exact Sciences stock higher after beating Q3 expectations, raising guidance By Investing.com - Investing.com South Africa
Exact Sciences Announces Third Quarter 2025 Results - Stock Titan
What candlestick patterns are forming on Exact Sciences CorporationGlobal Markets & Entry Point Confirmation Signals - newser.com
Exact Sciences Corporation stock chart pattern explainedJuly 2025 Market Mood & Low Drawdown Momentum Ideas - newser.com
Exact Sciences (EXAS) Q3 Earnings Preview: Positive Revisions Bo - GuruFocus
Exact Sciences Corporation Stock (EXAS) Opinions on Upcoming Earnings and Clinical Data - Quiver Quantitative
Should You Buy Exact Sciences Stock Before Nov. 3? - AOL.com
Nisa Investment Advisors LLC Acquires 4,500 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (EXAS) Reports Q3: Everything You Need To Know Ahead Of Earnings - Yahoo! Finance UK
Exact Sciences Corporation (EXAS) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
EXACT SCIENCES Earnings Preview: Recent $EXAS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Exact Sciences Corporation $EXAS Shares Sold by Jennison Associates LLC - MarketBeat
Brighton Jones LLC Takes $366,000 Position in Exact Sciences Corporation $EXAS - MarketBeat
KLCM Advisors Inc. Invests $212,000 in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences pulls out of major expansion project near Phoenix Sky Harbor - azcentral.com and The Arizona Republic
Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection - MSN
Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer - MSN
69,932 Shares in Exact Sciences Corporation $EXAS Acquired by Y Intercept Hong Kong Ltd - MarketBeat
Why Exact Sciences Corporation stock could see breakout soon2025 Market Trends & Expert Curated Trade Ideas - newser.com
Can Exact Sciences Corporation (EXK) stock hit consensus price targetsTrade Ideas & Daily Stock Momentum Reports - newser.com
One-on-One with David Harding of Exact Sciences - Modern Healthcare
A Look at Exact Sciences’s Valuation as New Cancer Screening Advances Debut at Major Gastroenterology Meeting - Yahoo Finance
Can Exact Sciences Corporation (EXK) stock stage a strong rebound this quarterIPO Watch & Daily Profit Maximizing Tips - newser.com
Zanotti of Exact Sciences sells $780k in stock By Investing.com - Investing.com UK
Leading vs lagging indicators on Exact Sciences Corporation performance2025 Performance Recap & Real-Time Chart Breakout Alerts - newser.com
Exact Sciences presents new colorectal cancer screening data at ACG By Investing.com - Investing.com Philippines
Is Exact Sciences Corporation stock a buy in volatile markets2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Insider Sell: Katherine Zanotti Sells 12,000 Shares of Exact Sci - GuruFocus
Zanotti of Exact Sciences sells $780k in stock - Investing.com
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
Exact Sciences Corp Director Katherine S Zanotti Sells 12,000 Shares - TradingView
Exact Sciences (MEX:EXAS) Other Stockholders Equity : MXN-0 Mil (As of Jun. 2025) - GuruFocus
How Exact Sciences Corporation (EXK) stock reacts to fiscal policiesQuarterly Risk Review & Low Risk High Reward Ideas - newser.com
Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Exact Sciences presents new colorectal cancer screening data at ACG - Investing.com
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps - The Globe and Mail
Peregrine Capital Management LLC Acquires 117,331 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Will Exact Sciences Corporation (EXK) stock announce special dividendJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):